IL2 and neoplasm: Another modified oncolytic adenovirus induces the expression of IL‐2 and TNF‐α (OAd/IL‐2/TNF‐α) could also boost the functions of mesothelin‐redirected CAR‐T cells.[171] It has been reported that combining modified oncolytic viruses expressing BiTE with CAR‐T cells can induce robust antitumor responses.[172] Folate receptor‐α (FR‐α) is a potent target for CAR‐T cell therapy because it is highly expressed in several tumor cells.[173, 174] However, due to the mechanisms of tumor cell escape by regulating the expression of FR‐α, monotherapy with anti‐FR‐α CAR‐T cells is ineffective.